iNMB per patient tested and empirically treated for iTTP for rapid (less than 1 hour) vs send-out (72 hours) and rapid (less than 1 hour) vs in-house (24 hours) testing over a 3-day time horizon
| Testing Strategy Comparison . | Cost (USD) . | Effectiveness (QALYs) . | Base-case iNMB (USD) (95% credible interval) . | Scenario iNMB (95% credible interval) . |
|---|---|---|---|---|
| PLASMIC = 5 (intermediate), TPE with caplacizumab | ||||
| Rapid vs send-out | 13 310 vs 60 130 | 0.0051 | 46 820 (41 960-52 490) | 46 810 (41 950-52 480) |
| Rapid vs in-house | 13 310 vs 34 020 | 0.0051 | 20 710 (19 050-22 630) | 20 700 (19 040-22 620) |
| PLASMIC = 5 (intermediate), TPE without caplacizumab | ||||
| Rapid vs send-out | 11 830 vs 27 770 | 0.0051 | 15 930 (11 130-21 530) | 15 930 (11 160-21 570) |
| Rapid vs in-house | 11 830 vs 17 050 | 0.0051 | 5 220 (3 590-7 100) | 5 220 (3 600-7 110) |
| PLASMIC = 6 or 7 (high), TPE with caplacizumab | ||||
| Rapid vs send-out | 50 960 vs 60 220 | 0.0051 | 9 530 (2 210-22 540) | 9 530 (2 210-22 540) |
| Rapid vs in-house | 50 960 vs 54 790 | 0.0051 | 4 100 (830-9 870) | 4 100 (830-9 970) |
| PLASMIC = 6 or 7 (high), TPE without caplacizumab | ||||
| Rapid vs send-out | 24 550 vs 21 810 | 0.0051 | 3 260 (730-8 190) | 3 260 (730-8 190) |
| Rapid vs in-house | 24 550 vs 25 510 | 0.0051 | 940 (90-2 630) | 940 (90-2 630) |
| Testing Strategy Comparison . | Cost (USD) . | Effectiveness (QALYs) . | Base-case iNMB (USD) (95% credible interval) . | Scenario iNMB (95% credible interval) . |
|---|---|---|---|---|
| PLASMIC = 5 (intermediate), TPE with caplacizumab | ||||
| Rapid vs send-out | 13 310 vs 60 130 | 0.0051 | 46 820 (41 960-52 490) | 46 810 (41 950-52 480) |
| Rapid vs in-house | 13 310 vs 34 020 | 0.0051 | 20 710 (19 050-22 630) | 20 700 (19 040-22 620) |
| PLASMIC = 5 (intermediate), TPE without caplacizumab | ||||
| Rapid vs send-out | 11 830 vs 27 770 | 0.0051 | 15 930 (11 130-21 530) | 15 930 (11 160-21 570) |
| Rapid vs in-house | 11 830 vs 17 050 | 0.0051 | 5 220 (3 590-7 100) | 5 220 (3 600-7 110) |
| PLASMIC = 6 or 7 (high), TPE with caplacizumab | ||||
| Rapid vs send-out | 50 960 vs 60 220 | 0.0051 | 9 530 (2 210-22 540) | 9 530 (2 210-22 540) |
| Rapid vs in-house | 50 960 vs 54 790 | 0.0051 | 4 100 (830-9 870) | 4 100 (830-9 970) |
| PLASMIC = 6 or 7 (high), TPE without caplacizumab | ||||
| Rapid vs send-out | 24 550 vs 21 810 | 0.0051 | 3 260 (730-8 190) | 3 260 (730-8 190) |
| Rapid vs in-house | 24 550 vs 25 510 | 0.0051 | 940 (90-2 630) | 940 (90-2 630) |
iNMB calculated for all scenario analyses (last column). All point estimates rounded to maximum 4 significant digits.
USD, US dollar.